Open AccessGenetically engineered mesenchymal stromal cells in cancer gene therapy
Author(s) -
Miroslava Matúšková,
Erika Durinikova,
Č Altaner,
Lenka Kučerová
Publication year - 2018
Publication title -
bratislavské lekárske listy/bratislava medical journal
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.387
H-Index - 32
eISSN - 1336-0345
pISSN - 0006-9248
DOI - 10.4149/bll_2018_041
Subject(s) - mesenchymal stem cell , stromal cell , cancer research , genetic enhancement , prodrug , cancer cell , medicine , cytotoxic t cell , cancer , disease , gene , biology , pathology , pharmacology , in vitro , biochemistry
Based on our experimental data, we aimed to emphasise the perspectives of the use of mesenchymal stromal cells (MSC) in the cancer gene therapy. On the other hand, we would like to point out factors which should be taken into consideration at their clinical use. In this review we define MSC as unique targets for targeted therapy. We proved the efficacy of experimental therapeutic approach utilising enzymatic conversion of non-toxic prodrug into chemotherapeutic by engineered MSC, and we observed significant cytotoxic effect in many preclinical models including metastatic disease. Treatment was enabled by affinity of MSC to tumour tissue and subsequent delivery of therapeutic molecule into the tumour. We also observed decreased efficacy of cell-mediated gene therapy on chemoresistant tumour cells. Moreover MSC can exert a supportive effect on tumour cells as well as to decrease the efficacy of conventional treatment. Besides obvious unique benefits connected to the use of MSC we pointed also to possible risks associated with their clinical application (Ref. 24).